Infections in patients with leukemia and lymphoma

Cancer Treatment and Research

Volumn 161, Issue , 2014, Pages 319-349

  Morrison, Vicki A ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Chronic lymphocytic leukemia; Hairy cell leukemia; Hodgkin lymphoma; Immunosuppression; Multiple myeloma; Neutropenia; Pathogenesis of Infection; Purine analog therapy

Indexed keywords

ALEMTUZUMAB; ALKYLATING AGENT; ANTIINFECTIVE AGENT; BORTEZOMIB; CHLORAMBUCIL; CLADRIBINE; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; FLUDARABINE; IMIDAZOLE; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INFLUENZA VACCINE; OBLIMERSEN; PENTOSTATIN; PLACEBO; PREDNISONE; RITUXIMAB;

ARTICLE; BACTERIAL INFECTION; BONE MARROW SUPPRESSION; CANCER MORTALITY; CELLULAR IMMUNITY; CELLULAR IMMUNODEFICIENCY; CHRONIC LYMPHATIC LEUKEMIA; COST EFFECTIVENESS ANALYSIS; CYTOMEGALOVIRUS INFECTION; DIVERTICULOSIS; HAIRY CELL LEUKEMIA; HODGKIN DISEASE; HUMAN; IMMUNE DEFICIENCY; IMMUNIZATION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFECTION PREVENTION; INFECTION RATE; INFECTION RISK; INFECTIOUS COMPLICATION; LARGE GRANULAR LYMPHOCYTE LEUKEMIA; LEUKEMIA; LOW DRUG DOSE; LYMPHOMA; MORBIDITY; MULTIPLE MYELOMA; MYCOSIS; MYELODYSPLASTIC SYNDROME; NAUSEA; NONHUMAN; OPPORTUNISTIC INFECTION; PARASITOSIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRIORITY JOURNAL; PYREXIA IDIOPATHICA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RISK FACTOR; SEPSIS; TOXIC EPIDERMAL NECROLYSIS; URINARY TRACT INFECTION; VIRUS INFECTION; MICROBIOLOGY; REVIEW;

ANTI-INFECTIVE AGENTS; HUMANS; INFECTION; LEUKEMIA; LYMPHOMA; RISK FACTORS;

EID: 84902073092     PISSN: 09273042     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-319-04220-6_11     Document Type: Article

References (224)

1. Wadhwa PD, Morrison VA (2006) Infectious complications of chronic lymphocytic leukemia. Semin Oncol 33:240-249
2. Morrison VA (2007) Management of infectious complications in patients with chronic lymphocytic leukemia. Hematology 332-338
3. Sinisalo M, Aittoniemi J, Koski T et al (2004) Similar humoral immunity parameters in chronic lymphocytic leukemia patients independent of VH gene mutation status. Leuk Lymphoma 45:2451-2454
4. Francis S, Karanth M, Pratt G, Starczynski J, Hooper L, Fegan C, Pepper C, Valcarcel D, Milligan DW, Delgado J (2006) The status on immunoglobulin VH gene mutation status and other prognostic factors on the incidence of major infections in patients with chronic lymphocytic leukemia. Cancer 107:1023-1033
5. Morrison VA, Hibbs JR, Janoff EN (1996) Systemic and mucosal immunoglobulin levels and risk of infection in patients with chronic lymphocytic leukemia and multiple myeloma. Blood 88:240a
6. Oshima K, Kanda Y, Nannya Y et al (2001) Clinical and pathologic findings in 52 consecutively autopsied cases with multiple myeloma. Am J Hematol 67:1-5
7. Jacobson DR, Zolla-Pazner S (1986) Immunosuppression and infection in multiple myeloma. Semin Oncol 282-290
8. Fahey JL, Scoggins R, Utz JP et al (1963) Infection, antibody response and gamma globulin concentrations in multiple myeloma and macroglobulinemia. Am J Med 35:698-707
9. Broder S, Humphrey R, Durm M et al (1975) Impaired synthesis of polyclonal (nonparaprotein) immunoglobulins by circulating lymphocytes from patients with multiple myeloma. N Engl J Med 293:887-892
10. Morell A, Terry WD, Waldmann TA (1970) Metabolic properties of IgG subclasses in man. J Clin Invest 49:673-680
11. Marks J (1953) Antibody formation in myelomatosis. J Clin Pathol 6:62-63
12. Lawson HA, Stuart CA, Paull AM et al (1955) Observations on the antibody content of the blood in patients with multiple myeloma. N Engl J Med 252:13-18
13. Heath RB, Hamilton F, Malpas JS (1964) Production of antibodies against viruses in leukaemia and related diseases. Br J Haematol 10:365-370
14. Fink PC, Galanos C (1985) Serum anti-lipid A antibodies in multiple myeloma and Waldenstrom’s macroglobulinaemia. Immunobiology 169:1-10
15. Stoll C, Schedel I, Peest D et al (1985) Serum antibodies against common antigens of bacterial lipopolysaccharides in healthy adults and patients with multiple myeloma. Infection 13:115-119
16. Van Camp B, Reynaert PH, Broodtaerts L (1981) Studies on the origin of the precursor cells in multiple myeloma, Waldenstrom’s macroglobulinemia and benign monoclonal gammopathy. I. Cytoplasmic isotype and idiotype distribution in peripheral blood and bone marrow. Clin Exp Imunol 44:82-89
17. Dillman RO, Royston I, Meserve BL et al (1981) Alterations of peripheral blood B-lymphocyte populations in plasma cell disorders. Cancer 48:2211-2217
18. King MA, Wells JV (1981) Cell-bound immunoglobulin on peripheral blood mononuclear cells of patients with myeloma. Clin Exp Immunol 45:522-556
19. Bast EJEG, Van Camp B, Reynaert P et al (1982) Idiotypic peripheral blood lymphocytes in monoclonal gammopathy. Clin Exp Immunol 47:677-682
20. Pilarski LM, Mant MJ, Ruether BA et al (1984) Severe deficiency of B lymphocytes in peripheral blood from multiple myeloma patients. J Clin Invest 74:1301-1306
21. Lindstrom FD, Hardy WR, Eberle BJ et al (1973) Multiple myeloma and benign monoclonal gammopathy: differentiation by immunofluorescence of lymphocytes. Ann Intern Med 78:837-844
22. Abdou NI, Abdou NL (1975) The monoclonal nature of lymphocytes in multiple myeloma. An Intern Med 83:42-45
23. Chen Y, Bhoopalam N, Yakulis BS et al (1975) Changes in lymphocyte surface immunoglobulins in myeloma and the effect of an RNA-containing plasma factor. Ann Intern Med 83:625-631
24. Glenchur H, Zinnerman HH, Hall WH (1959) A review of fifty-one cases of multiple myeloma. Arch Intern Med 103:173-183
25. Cone L, Uhr JW (1964) Immunological deficiency disorders associated with chronic lymphocytic leukemia and multiple myeloma. J Clin Invest 43:2241-2248
26. Zinneman HH, Hall WH (1954) Recurrent pneumonia in multiple myeloma and some observations on immunologic response. Ann Intern Med 41:1152-1163
27. Larson DL, Tomlinson LJ (1952) Quantitative antibody studies in man. II. The relation of the level of serum proteins to antibody production. J Lab Clin Med 39:129-134
28. Lazarus HM, Lederman M, Lubin A et al (1980) Pneumococcal vaccination: the response of patients with multiple myeloma. Am J Med 69:419-423
29. Schidt RA, Rubin RR, Schiffman G et al (1981) polyvalent pneumococcal immunization of patients with plasma cell dyscrasias. Cancer 48:1377-1380
30. Birgens HS, Espersen F, Hertz JB et al (1983) Antibody response to pneumococcal vaccination in patients with myelomatosis. Scand J Haematol 30:324-330
31. Cheson BD, Plas PR, Rothstein G (1980) Defective opsonization in multiple myeloma. Blood 55:602-606
32. Kraut EH, Sagone AL (1981) Alternate pathway of complement in multiple myeloma. Am J Hematol 11:335-345
33. Cheson BD, Walker HS, Heath ME et al (1984) Defective binding of the third component of complement (C3) to Streptococcus pneumoniae in multiple myeloma. Blood 63:949-957
34. MacGregor RR, Negendank WG, Schreiber AD (1978) Impaired granulocyte adherence in multiple myeloma: relationship to complement system, granulocyte delivery, and infection. Blood 51:591-599
35. Spitler LE, Spath P, Petz L et al (1975) Phagocytes and C4 in paraproteinaemia. Br J Haematol 29:279-292
36. Penny R, Galton DAG (1966) Studies on neutrophil function II. Pathological aspects. Br J Haematol 12:633-645
37. Hopen G, Glette J, Halstensen A et al (1983) Granulocyte function in malignant monoclonal gammopathy. Scand J Haematol 31:133-143
38. Ziegler JB, Hansen PJ, Penny R (1975) Leucocyte function in paraproteinemia. Aust NZ J Med 5:39-43
39. Naess A, Hopen G, Solberg CO (1984) Decrease of Fcc and C3b receptor-bearing granulocytes and of T lymphocytes in myelomatosis. Scand J Haematol 33:83-90
40. Dammacco F, Miglietta A, Ventura MT et al (1982) Defective monocyte chemotactic responsiveness in patients with multiple myeloma and benign monoclonal gammopathy. Clin Exp Immunol 47:481-486
41. Blom J, Nielsen H, Larsen SO et al (1984) A study of certain functional parameters of monocytes from patients with multiple myeloma: comparison with monocytes from healthy individuals. Scand J Haematol 33:425-431
42. Fahey JL, Humphrey JH (1962) Effect of transplantable plasma-cell tumors on antibody response in mice. Immunology 5:110-115
43. Havas HF, Schiffman G (1978) The effect of an IgM plasmacytoma (TEPC-183) on the primary immune response of BALB/c mice. Immunology 34:1-8
44. Smith F, Grenan ZMM, Owens J (1960) Effect of a transplanted plasma-cell tumor on antibody formation. J Natl Cancer Inst 25:803-812
45. Zolla S (1972) The effect of plasmacytomas on the immune response of mice. J Immunol 108:1039-1048
46. Hirano S, Imamura Y, Takaku F et al (1968) Immune response in mice with plasma-cell tumor (X5563) assayed by agar plaque technique. Blood 31:252-257
47. Zolla S, Naor D, Tanapatchaiyapong P (1974) Cellular basis of immunodepression in mice with plasmacytomas. J Immunol 112:2068-2076
48. Ullrich S, Zolla-Pazner S (1982) Immunoregulatory circuits in myeloma. Clin Haematol 11:87-111
49. Tanapatchaiyapong P, Zolla S (1974) Humoral immunosuppressive substance in mice bearing plasmacytomas. Science 186:748-750
50. Kolb J-P, Arrian S, Zolla-Pazner S (1977) Suppression of the humoral immune response by plasmacytomas: mediation by adherent mononuclear cells. J Immunol 118:702-709
51. Kennard J, Zolla-Pazner S (1980) Origin and function of suppressor macrophages in myeloma. J Immunol 124:268-273
52. Krakauer RS, Strober W, Waldmann TA (1977) Hypogammaglobulinemia in experimental myeloma: the role of suppressor factors from mononuclear phagocytes. J Immunol 118:1385-1390
53. Katzmann JA (1978) Myeloma-induced immunosuppression: a multistep mechanism. J Immunol 121:1405-1409
54. Hamburger AW (1980) Inhibition of B-lymphocyte clonal proliferation by spleen cells from plasmacytoma-bearing mice. J Natl Cancer Inst 65:1337-1343
55. Berman JE, Zolla-Pazner S (1985) Control of B cell proliferation: inhibition of responses to B cell mitogens induced by plasma cell tumors. J Immunol 134:2872-2878
56. Hoover RG, Dieckgraefe BK, Lake J et al (1982) Lymphocyte surface membrane immunoglobulin in myeloma. III. IgA plasmacytomas induce large numbers of circulating, adult thymectomy-sensitive, q+, Lyt-1 -2+ lymphocytes with IgA-Fc receptors. J Immunol 129:2329-2331
57. Hoover RG, Lynch RG (1983) Isotype-specific suppression of IgA: suppression of IgA responses in BALB/c mice by Ta cells. J Immunol 130:521-523
58. Hoover RG, Dieckgraefe BK, Lynch RG (1981) T cells with Fc receptors for IgA: induction of T cells in vivo and in vitro by purified IgA. J Immunol 127:1560-1563
59. Mather A, Lynch RG (1986) Increased Tc and Tl cells in BALB/c mice with Ig G and IgM plasmacytomas and hybridomas. J Immunol 136:521-525
60. Muller S, Hoover RG (1985) T cells with Fc receptors in myeloma: suppression of growth and secretion of MOPC-315 by Ta cells. J Immunol 134:644-647
61. Jones SV, McFarlane H (1975) T and B cells in myelomatosis. Br J Haematol 31:545-552
62. Sato I, Abo T, Onodera S et al (1978) Detection of monoclonal B lymphocytes in multiple myeloma by immunofluorescence tests of surface immunoglobulins. Scand J Haematol 21:433-444
63. Kubagawa W, Vogler LB, Capra JD et al (1979) Studies on the clonal origin of multiple myeloma: use of individually specific (idiotype) antibodies to trace the oncogenic event to its earliest point of expression in B-cell differentiation. J Exp Med 150:792-807
64. Schedel I, Peest D, Stunkel K et al (1980) Idiotype-bearing peripheral blood lymphocytes in human multiple myeloma and Waldenstrom’s macroglobulinemia. Scand J Immunol 11:437-444
65. Carmagnola AL., Boccadoro M, Massaia M et al (1983) The idiotypic specificities of lymphocytes in human monoclonal gammopathies: analysis with the fluorescence activated cell sorter. Clin Exp Immunol 51:173-177
66. Leonard RCF, MacLennan CM, Smart Y et al (1979) Light chain isotype-associated suppression of normal plasma cell number in patients with multiple myeloma. Int J Cancer 24:385-393
67. Werne A, Joshua DE, Kronenberg H (1984) Light chain isotype associated suppression of surface immunoglobulin expression on peripheral blood lymphocytes in myeloma during plateau phase. Br J Haematol 58:483-489
68. Kraut E (2003) Clinical manifestations and infectious complications of hairy-cell leukaemia. Best Pract Res Clin Haematol 16(1):33-40
69. Offerman MK, Golomb H (1984) Hairy cell leukemia. Curr Probl Cancer 8(7):1-39
70. Golomb H, Hadad L (1984) Infectious complications in 127 patients with hairy cell leukemia. Am J Hematol 16:393-401
71. Stewart DJ, Gp B (1981) Infections in hairy cell leukemia. Cancer 15:801-805
72. Mackowiak P, Demian S, Sutker W et al (1980) Infections in hairy cell leukemia, clinical evidence of a pronounced defect in cell-mediated immunity. Am J Med 68:718-723
73. Bouza E, Burgaleta C, Golde D (1978) Infections in hairy-cell leukemia. Blood 51(5):851-859
74. Kraut EH, Grever MR, Bourouncle B (1994) Long term follow-up of patients with hairy cell leukemia after treatment with 200 deoxycoformycin. Blood 84:4061-4063
75. Goodman G, Burian C, Koziol J et al (2003) Extended follow-up of patients with hairy cell leukemia after treatment with cladribine. J Clin Oncol 25(5):891-896
76. Child JA, Cawley JC, Martin S (1979) Microbicidal function of the neutrophils in hairy cell leukemia. Acta Haematol 62:191-198
77. Yam LT, Chaudhry AA, Janckila AJ (1977) Impaired marrow granulocyte reserve and leukocyte mobilization in leukemic reticuloendotheliosis. Ann Intern Med 87:444-446
78. Kjeldsberg CR (1978) Leukocyte mobilization in leukemic reticuloendotheliosis (letter). Ann Intern Med 88:268-269
79. Seshadri R, Brown E, Zipursky A (1976) Leukemic reticuloendotheliosis: a failure of monocyte production. New Engl J Med 295:181-184
80. Ruco LP, Procopio A, Maccanallini V (1983) Severe deficiency of natural killer cell activity in the peripheral blood of patients with hairy cell leukemia. Blood 61:1131-1137
81. Bourguin-Pionquet A, Rouard H, Roudot-Thoraval F (2002) Severe decrease in peripheral blood dendritic cells in hairy cell leukemia. Brit J Haematol 116:595-597
82. Damaj G, Kuhnowski F, Marolleau JP et al (2009) Risk factors for severe infection in patients with hairy cell leukemia: a long-term study of 73 patients. Eur J Haematol 83:246-250
83. Golomb H, Hanauer S (1981) Infectious complications associated with hairy cell leukemia. J Infect Dis 143:639-643
84. Berliner N (1990) T gamma lymphocytosis and T cell chronic leukemias. Hematol Oncol Clin North Am 4:473-487
85. Mohan SR, Maciejewski JP (2009) Diagnosis and therapy of neutropenia in large granular lymphocytic leukemia. Curr Opin Hematol 16:27-34
86. Loughran TP, Starkebaum G (1987) Large granular lymphocytic leukemia: report of 38 cases and review of the literature. Medicine 66:397-405
87. Casazza AR, Duvall CP, Carbone PP (1966) Summary of infectious complications occurring in patients with Hodgkin’s disease. Cancer Res 26:1290-1296
88. Colby TV, Richard TH, Roger AW (1981) Hodgkin’s disease and autopsy. Cancer 47:1852-1862
89. Romagnani S, Ferrini PLR, Ricci M (1985) The immune derangement in Hodgkin’s disease. Semin Hematol 22:41-55
90. Baldwin RW (1972) Immunological aspects of Hodgkin’s disease. Proc R Soc Med 65:1113
91. Gupta S (1981) Immunodeficiencies in Hodgkin’s disease. Part I: T cell-mediated immunity. Clin Bull 11:58-65
92. Bjorkholm M, Wedelin C, Holm G, Ogenstad S, Johansson B, Mellstedt H (1982) Immune status of untreated patients with Hodgkin’s disease and prognosis. Cancer Treat Rep 66:701-709
93. Bjorkholm M (1978) Immunodeficiency in Hodgkin’s disease and its relation to prognosis. Scand J Haematol 33(Suppl):7-74
94. Holm G, Mellstedt H, Bjorkholm M, Johansson B, Killander D, Sundblad R, Soderberg G (1976) Lymphocyte abnormalities in untreated patients with Hodgkin’s disease. Cancer 37:751-762
95. Hunter CP, Tannenbaum H, Churchill WH, Moloney WC, Schur PH (1997) Immunologic abnormalities in patients with malignant lymphoproliferative diseases. J Natl Cancer Inst 58:11185-11190
96. Franzke A, Koenecke C, Geffers R, Piao W, Hunger JK, Ganser A, Buer J (2006) Classical Hodgkin lymphoma: molecular evidence for specific alterations in circulating T lymphocytes. Tumour Biol 27:329-333
97. Levy R, Kaplan HS (1974) Impaired lymphocyte function in untreated Hodgkin’s disease. N Engl J Med 290:181-186
98. Graze PR, Perlin E, Royston I (1976) In vitro lymphocyte dysfunction in Hodgkin’s disease. J Natl Cancer Inst 56:239-243
99. Hillinger SM, Herzig GP (1978) Impaired cell-mediated immunity in Hodgkin’s disease mediated by suppressor lymphocytes and monocytes. J Clin Invest 61:1620-1627
100. Twomey JJ, Laughter AH, Rice L, Ford R (1980) Spectrum of immunodeficiencies with Hodgkin’s disease. J Clin Invest 66:629-637
101. Aisenberg AC (1964) Hodgkin’s disease: prognosis, treatment, and etiologic and immunologic considerations. New Engl J Med 270:508-514, 565-570, 617-622
102. Aisenberg AC, Leskowitz S (1963) Antibody formation in Hodgkin’s disease. New Engl J Med 268:1269-1272
103. Kelly WD, Lamb DL, Varco RL, Good RA (1960) An investigation of Hodgkin’s disease with respect to the problem of homotransplantation. An NY Acad Sci 87:187-202
104. Brown RS, Haynes RA, Foley HT (1967) Hodgkin’s disease: immunological, clinical, and histological features of 50 untreated patients. Ann Intern Med 67:291-300
105. Eltringham JR, Kaplan HS (1973) Impaired delayed hypersensitivity responses in 154 patients with untreated Hodgkin’s disease. Natl Cancer Inst Monogr 36:107-115
106. Del Giacco GS, Manconi PE, Tognella S, Mantovani G, Grifoni V (1972) Delayed hypersensitivity in Hodgkin’s disease. Boll Soc Ital Biol Sper 48:377-381
107. Winkelstein A, Mikulla JM, Sartiano GP, Ellis LD (1974) Cellular immunity in Hodgkin’s disease: comparison of cutaneous reactivity and lymphoproliferative responses to phytohemagglutinin. Cancer 34:549-553
108. Shiftan TA, Caviles AP Jr, Mendelsohn J (1978) Spontaneous lymphocyte proliferation and depressed cellular immunity in Hodgkin’s disease. Clin Exp Immunol 32:144-152
109. Ford RJ, Tsao J, Kouttab NM, Sahasrabuddhe CG, Mehta SR (1984) Association of an interleukin abnormality with the T cell defect in Hodgkin’s disease. Blood 64:386-392
110. Young RC, Corder MP, Haynes HA (1972) Delayed hypersensitivity in Hodgkin’s disease: a study of 103 untreated patients. Amer J Med 52:63-72
111. Aisenberg AC (1973) Malignant lymphoma. New Engl J Med 288:883-889
112. Young RC, Corder MP, Berard CW, DeVita VT (1973) Immune alterations in Hodgkin’s disease: effect of delayed hypersensitivity and lymphocyte transformation on course and survival. Arch Intern Med 131:446-454
113. Schier WW, Roth A, Ostroff G, Schrift MH (1956) Hodgkin’s disease and immunity. Am J Med 20:94-99
114. Jackson SM, Garrett JV, Craig AW (1970) Lymphocyte transformation changes during the clinical course of Hodgkin’s disease. Cancer 25:843-850
115. Amlot PL, Slaney JM, Williams BD (1976) Circulating immune complexes and symptoms in Hodgkin’s disease. Lancet 1:449-451
116. Brown CA, Hall CL, long J (1978) Circulating immune complexes in Hodgkin’s disease. Am J Med 64:289-294
117. Heier HE, Klepp R, Gundersen S (1977) Blood B and T lymphocytes and in vitro cellular immune reactivity in untreated human malignant lymphomas and other malignant tumors. Scand J Haematol 18:137-148
118. Van Rijswijk RE, Sybesma JP, Kater L (1983) A prospective study of the changes in the immune status before, during, and after multiple-agent chemotherapy for Hodgkin’s disease. Cancer 51:637-644
119. Bjorkholm M, Holm G, Mellstedt H (1977) Immunologic profile of patients with cured Hodgkin’s disease. Scand J Haematol 18:361-368
120. Hancock BW, Bruce L, Dunsmore IR, Ward AM, Richmond J (1977) Follow-up studies on the immune status of patients with Hodgkin’s disease after splenectomy and treatment, in relapse and remission. Br J Cancer 36:347-354
121. Hancock BW, Bruce L, Whitham MD, Dunsmore IR, Ward AM, Richmond J (1982) Immunity in Hodgkin’s disease: status after 5 years’ remission. Br J Cancer 46:593-600
122. Fisher RI, DeVita VT, Bostick F, Vanhaelen C, Howser DM, Hubbard SM, Young RC (1980) Persistent immunologic abnormalities in long-term survivors of advanced Hodgkin’s disease. Ann Intern Med 92:595-599
123. Skovmann-Sorensen O, Schroder H, Moller-Larsen A, Haahr S (1981) Cellular and humoral immunity in Hodgkin’s disease. I. Patients in continuous long-term remission. Scand J Haematol 27:171-180
124. Pomeroy C, Oken MM, Rydell RE, Filice GA (1991) Infection in the myelodysplastic syndromes. Am J Med 90:338-344
125. Martin S, Baldock SC, Ghoneim A, Child JA (1983) Defective neutrophil function and microbicidal mechanisms in the myelodysplastic disorders. J Clin Pathol 36:1120-1128
126. Cech P, Markert M, Perrin LH (1983) Partial myeloperoxidase deficiency in preleukemia. Blut 47:21-30
127. Scott CS, Cahill A, Bynoe AG, Aihley MJ, Hough D, Roberts BE (1983) Esterase cytochemistry in primary myelodysplastic syndrome and megaloblastic anemia. Br J Haematol 55:411-418
128. Boogaerts MA, Nelissen V, Roelant C, Goosens W (1983) Blood neutrophil function in primary myelodysplastic syndrome. Br J Haematol 55:217-227
129. Ruutu P (1986) Granulocyte function in myelodysplastic syndrome. Scand J Haematol 36(Suppl 45):66-70
130. Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissig R, Stone RM, Nelson D, Powell BL, DeCastro CM, Ellerton J, Larson RA, Schiffer CA, Holland JF (2002) Randomized controlled trial of azacytidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 20:2429-2440
131. Silverman LR, McKenzie DR, Peterson BL, Holland JF, Backstrom JT, Beach CL, Larson RA (2006) Further analysis of trials with azacytidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the cancer and leukemia group B. J Clin Oncol 3895-3903
132. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, Schoch R, Gattermann N, Sanz G, List A, Gore SD, Seymour JF, Bennett JM, Byrd J, Backstrom J, Zimmerman L, McKenzie D, Beach CL, Silverman LR (2009) Efficacy of azacytidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndrome: a randomized, open-label, phase III study. Lancet Oncol 10:223-232
133. Personal communication, Dr. Kanti Rai. June 1998
134. Cheson BD (1995) Infectious and immunosuppressive complications of purine analog therapy. J Clin Oncol 13:2431-2448
135. Morrison VA, Rai KR, Peterson B et al (2001) Impact of therapy with chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: intergroup study cancer and leukemia group B 9011. J Clin Oncol 19:3611-3621
136. Anaissie EJ, Kontoyiannis DP, O’Brien S et al (1998) Infections in patients with chronic lymphocytic leukemia treated with fludarabine. Ann Intern Med 129:559-566
137. Hensel M, Kornacker M, Yammeni S et al (2003) Disease activity and pretreatment, rather than hypogammaglobulinemia, are major risk factors for infectious complications in patients with chronic lymphocytic leukemia. Br J Haematol 122:600-606
138. Steurer M, Pall G, Richards S et al (2006) Single-agent purine analogues for the treatment of chronic lymphocytic leukaemia: a systematic review and meta-analysis. Cancer Treat Rev 32:377-389
139. Leporrier M, Chevret S, Cazin B et al (2001) Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood 98:2319-2325
140. Eichhorst BF, Busch R, Hopfinger G et al (2006) Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood 107:885-891
141. O’Brien S, Moore JO, Boyd TE et al (2007) Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol 25:1114-1120
142. Kowal M, Dmoszynska A, Lewandowski K et al (2004) Efficacy and safety of fludarabine and cyclophosphamide combined therapy in patients with refractory/recurrent B-cell chronic lymphocytic leukaemia (B-CLL): polish multicentre study. Leuk Lymphoma 45:1159-1165
143. Hainsworth JD, Litchy S, Barton JH et al (2003) Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 21:1746-1751
144. Byrd JC, Peterson BL, Morrison VA et al (2003) Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from cancer and leukemia group B 9712 (CALGB 9712). Blood 101:6-14
145. Keating MJ, O’Brien S, Albitar M et al (2005) Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 23:4079-4088
146. Wierda W, O’Brien S, Wen S et al (2005) Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 23:4070-4078
147. Robak T, Blonski JZ, Urbanska-Rys H, Blasinska-Morawiec M, Skotnicki AB (1999) 2-chlorodeoxyadenosine (cladribine) in the treatment of patients with chronic lymphocytic leukemia 55 years old and younger. Leukemia 13:518-523
148. Byrd JC, Peterson B, Piro L et al (2003) A phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic leukemia: results from CALGB study 9211. Leukemia 17:323-327
149. Robak T, Blonski JZ, Kasznicki M et al (2000) Cladribine with or without prednisone in the treatment of previously treated and untreated B-cell chronic lymphocytic leukaemia: updated results of the multicentre study of 378 patients. Br J Haematol 108:357-368
150. Robak T, Blonski JZ, Kasznicki M et al (2000) Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial. Blood 96:2723-2729
151. Dillman RO, Mick R, McIntyre OR (1989) Pentostatin in chronic lymphocytic leukemia: a phase II trial of cancer and leukemia group B. J Clin Oncol 7:433-438
152. Oken MM, Lee S, Kay NE et al (2004) Pentostatin, chlorambucil and prednisone therapy for B-chronic lymphocytic leukemia: a phase I/II study by the Eastern Cooperative Oncology Group study E1488. Leuk Lymphoma 45:79-84
153. Lamanna N, Kalaycio M, Maslak P et al (2006) Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia. J Clin Oncol 24:1575-1581
154. Shanafelt TD, Lin T, Geyer SM et al (2007) Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemia. Cancer 109:2291-2298
155. Keating MJ, Flinn I, Jain V et al (2002) Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 99:3554-3561
156. Hillmen P, Skotnicki AB, Robak T et al (2007) Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol 25:5616-5623
157. Martin SI, Marty FM, Fiumara K et al (2006) Infectious complications associated with alemtuzumab use for lymphoproliferative disorders. Clin Infect Dis 43:16-24
158. Elter T, Borchmann P, Schulz H et al (2005) Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial. J Clin Oncol 23:7024-7031
159. Faderl S, Thomas DA, O’Brien S et al (2003) Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood 101:3413-3415
160. O’Brien SM, Kantarjian HM, Thomas DA et al (2003) Alemtuzumab as treatment for residual diseased after chemotherapy in patients with chronic lymphocytic leukemia. Cancer 98:2657-2663
161. Montillo M, Cafro AM, Tedeschi A et al (2002) Safety and efficacy of subcutaneous Campath-1H for treating residual disease in patients with chronic lymphocytic leukemia responding to fludarabine. Haematologica 87:695-700
162. Wendtner CM, Ritgen M, Schweighofer CD et al (2004) Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission: experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia 18:1093-1101
163. Rai KR, Byrd JC, Peterson BL, Larson RA (2002) A phase II trial of fludarabine followed by alemtuzumab in previously untreated chronic lymphocytic leukemia (CLL) patients with active disease: cancer and leukemia group B (CALGB) study 19901. Blood 100:205-206a
164. Rai KR, Byrd JC, Peterson BL et al (2003) Subcutaneous alemtuzumab following fludarabine for previously untreated patients with chronic lymphocytic leukemia (CLL): CALGB study 19901. Blood 102:676-677a
165. Morrison VA, Peterson BL, Rai KR et al (2007) Alemtuzumab increases serious infections in patients with previously untreated chronic lymphocytic leukemia (CLL) receiving fludarabine-based therapy: a comparative analysis of 3 cancer and leukemia group B studies (CALGB 9011, 9712, 19901). Blood 110:233a
166. Lin T, Donohue KA, Lucas MS et al (2007) Consolidation therapy with subcutaneous (SC) alemtuzumab results in serious infectious toxicity in previously untreated CLL patients who achieve a complete remission (CR) after fludarabine and rituximab (FR) induction therapy: Interim safety analysis of the CALGB study 10101. Blood 110:232-233a
167. Costa AJH, Costa DB, Shin B, Cooper DL (2004) Pneumococcemia as the presenting feature of multiple myeloma. Am J Heamtol 77:277-281
168. Perri RT, Hebbel R, Oken MM (1981) Influence of treatment and response status on infection risk in multiple myeloma. Am J Med 71:935-938
169. Rayner C, Haynes AP, Thompson JR et al (1991) Perspectives in multiple myeloma: survival, prognostic factors and disease complications in a single center between 1975 and 1988. Q J Med 290:517-525
170. Savage DG, Lindenbaum J, Garrett TJ (1982) Biphasic pattern of bacterial infection in multiple myeloma. An Intern Med 96:47-50
171. Meyers BR, Hirschman SZ, Axelrod JA (1972) Current patterns of infection in multiple myeloma. Am J Med 52:87-92
172. Espersen F, Birgens HS, Hertz JB et al (1984) Current patterns of infection in myelomatosis. Scan J Infect Dis 16:169-173
173. Shaikh BS, Lombard RM, Appelbaum PC et al (1982) Changing patterns of infection in patients with multiple myeloma. Oncology 39:78-82
174. Twomey JT (1973) Infections complicating multiple myeloma and chronic lymphocytic leukemia. Arch Int Med 132:562-565
175. Lortholary O, Ascioglu S, Moreau P et al (2000) Invasive aspergillosis as an opportunistic infection in nonallografted patients with multiple myeloma: a European Organization for Research and Treatment of Cancer. Clin Infect Dis 30:41-46
176. Richardson PG, Sonneveld P, Schuster MW et al (2005) Bortezomib or high dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352:2487-2498
177. Chanan-Khan A, Sonneveld P, Schuster MW et al (2008) Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. J Clin Oncol 26:4784-4790
178. Kim SJ, Kim K, Kim BS et al (2008) Bortezomib and the increased incidence of herpes zoster in patients with multiple myeloma. Clin Lymph Myeloma 8:237-240
179. Bennett C, Vardiman J, Golomb H (1986) Disseminated atypical mycobacterial infection in patients with hairy cell leukemia. Am J Med 80:891-896
180. Weinstein RA, Golomb HM, Grumet G, Gelmann E, Schechter GP (1981) Hairy cell leukemia: association with disseminated mycobacterial infection. Cancer 48:380-383
181. Weinstein RA, Gelmann E, Golomb HM (1978) Disseminated atypical mycobacteria infection in hairy cell leukemia (letter). Lancet 2:1052
182. Rice L, Shenkenberg T, Lynch C, Wheeler TM (1982) Granulomatous infections complicating hairy cell leukemia. Cancer 49:1924-1928
183. Gallo JH, Young GAR, Forrest PR, Vincent PC, Jennis F (1983) Disseminated atypical mycobacteria infection in hairy cell leukemia. Pathology 15:241-245
184. Weeks E, Jones CM, Guinee V (1992) Histoplasmosis in hairy cell leukemia: case report and review of the literature. Ann Hematol 65:138-142
185. Audeh YM, Gruszecki AC, Cherrington A (2003) Hairy cell leukemia with concurrent cryptococcus infection. Am J Hematol 72:223-224
186. Bennett CL, Westbrook CA, Gruber B (1986) Hairy cell leukemia and mucormycosis. Am J Med 81:1065-1067
187. Ma B, Seymour JF, Januszewicz H (2001) Cure of pulmonary Rhizopus pusillis infection in a patient with hairy cell leukemia: role of liposomal amphotericin B and GM-CSF. Leuk Lymphoma 42:1393-1399
188. Hoffman M (2006) Clinical presentations and complications of hairy cell leukemia. Hematol Oncol Clin North Am 20:1065-1073
189. Edelman MJ, O’Donnell RT, Meadows I (1997) Treatment of refractory large granular lymphocytic leukemia with 2-chlorodeoxyadenosine. Am J Hematol 54:329-331
190. Fujishima N, Sawada K, Hirokawa M, Oshimi K, Sugimoto K, Matsuda A, Teramura M, Karasawa M, Arai A, Yonemura Y, Nakao S, Omine M, Ozawa K (2008) Long-term responses and outcomes following immunosuppressive therapy in large granular lymphocytic leukemia-associated pure red cell aplasia: a nationwide cohort study in Japan for the PRCA Collaborative Study Group. Haematologica 93:1555-1559
191. Bartlett NL, Longo DL (1999) T-small lymphocytic disorders. Semin Hematol 36:164-170
192. Weide R, Heymanns J, Koppler H, Tiemann M, Huss B, Pfluger KH, Havemann K (1994) Successful treatment of neutropenia in T-LGL leukemia (T gamma-lymphocytosis) with granulocyte colony stimulating factor. Ann Hamatol 69:117-119
193. Loughran TP (1993) Clonal diseases of large granular lymphocytes. Blood 82:1-14
194. Loughran TP, Kidd PG, Starkebaum G (1994) Treatment of large granulocyte lymphocyte leukemia with oral low-dose methotrexate. Blood 84:2164-2170
195. Casazza AR, Duvall CP, Carbone PP (1966) Infection in lymphoma: histology, treatment, and duration in relation to incidence and survival. JAMA 197:118-124
196. Casazza AR, Duvall CP, Carbone PP (1966) Summary of infectious complications occurring in patients with Hodgkin’s disease. Cancer Res 26:1290-1296
197. Cohen S, Fisher B, Yoshida T (1974) Serum-migration inhibitory activity in patients with lymphoproliferative disease. N Engl J Med 290:882-886
198. Aisenberg AC (1962) Studies on delayed hypersensitivity in Hodgkin’s disease. J Clin Invest 1964-1970
199. Gendel BR, Ende M, Norman SL (1950) Cryptococcosis: a review with special reference to apparent association with Hodgkin’s disease. Am J Med 9:343-355
200. Hutter RVP, Collins HS (1962) The occurrence of opportunistic fungus infections in a cancer hospital. Lab Invest 11:1035-1045
201. Shanbrom E, Miller S, Haar H (1960) Herpes zoster in hematologic neoplasias: some unusual manifestations. Ann Intern Med 53:523-533
202. Parker F, Jackson H, Bethea JM, Otis F (1932) Studies of diseases of lymphoid and myeloid tissues; coexistence of tuberculosis with Hodgkin’s disease and other forms of malignant lymphoma. Am J M Sci 184:694-699
203. Zimmerman LE, Rappaport H (1954) Occurrence of cryptococcosis in patients with malignant disease of reticuloendothelial system. Am J Clin Path 24:1050-1072
204. Feldman S, Hughes WT, Daniel CB (1975) Varicella in children with cancer: seventy-seven cases. Pediatrics 56:388-397
205. Arvin AM, Pollard RB, Rasmussen LE et al (1980) Cellular and humoral immunity in the pathogenesis of recurrent herpes viral infections in patients with lymphoma. J Clin Invest 68:869-878
206. Whitley RJ (1984) Varicella zoster infections. In: Galasso G, Merigan T, Buchanan R (eds) Antiviral agents and viral infections of man. Raven Press, New York, pp 517-541
207. Schimpff S, Serpick A, Stoler B et al (1972) Varicella-zoster infection in patients with cancer. Ann Intern Med 76:241-254
208. Shambrom E, Miller S, Haar H (1960) Herpes zoster in hematologic neoplasias: some unusual manifestations. Ann Intern Med 53:523-533
209. Wright ET, Winer LH (1961) Herpes zoster and malignancy. Arch Dermat 84:242-247
210. Goffinet DR, Glatstein EJ, Merigan TC (1972) Herpes zoster—varicella infections and lymphoma. Ann Intern Med 76:235-240
211. Mazur MH, Dolin R (1978) Herpes zoster at the NIH: a 20 year experience. Am J Med 65:738-744
212. Arvin AM, Pollard RB, Rasmussen LE et al (1978) Selective impairment of lymphocyte reactivity to varicella-zoster virus antigen among untreated patients with lymphoma. J Infect Dis 137:531-540
213. Sokol SE, Firat D (1965) Varicella-zoster infection in Hodgkin’s disease. Am J Med 39:452-463
214. Guinee VF, Guido JJ, Pfalzgraf KA et al (1985) The incidence of herpes zoster in patients with Hodgkin’s disease: an analysis of prognostic factors. Cancer 56:642-647
215. Ruckdeschel JC, Schimpff SC, Smyth AC et al (1977) Herpes zoster and impaired cellassociated immunity to the varicella-zoster virus in patients with Hodgkin’s disease. Am J Med 62:77-85
216. Cooperative group for the study of immunoglobulin in chronic lymphocytic leukemia (1988) Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. N Engl J Med 319:902-907
217. Morrison VA, Byrd JC, Peterson BL et al (2003) Adding rituximab to fludarabine therapy for patients with untreated chronic lymphocytic leukemia (CLL) does not increase the risk of infection: cancer and leukemia group B (CALGB) study [abstract]. Blood 102:440a
218. O’Brien S, Keating MJ, Mocarski ES (2006) Updated guidelines on the management of cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab. Clin Lymphoma Myeloma 7:125-130
219. Smith TF, Espy MJ, Mandrekar J et al (2007) Quantitative real-time polymerase chain reaction for evaluating DNAemia due to cytomegalovirus, Epstein-Barr virus, and BK virus in solid-organ transplant recipients. Clin Infect Dis 45:1056-1061
220. O’Brien S, Ravandi-Kashani F, Wierda WG et al (2005) A randomized trial of valacyclovir versus valganciclovir to prevent CMV reactivation in patients with CLL receiving alemtuzumab. Blood 106:830a
221. Oken MM, Pomeroy C, Weisdorf D et al (1996) Prophylactic antibiotics for the prevention of infection in multiple myeloma. Am J Med 100:624-628
222. Health and Public Policy Committee (1986) Position papers: pneumococcal vaccine. Ann Intern Med 104:118-120
223. Salmon SE, Samal BA, Hayes DM et al (1967) Role of gamma globulin for immunoprophylaxis in multiple myeloma. N Engl J Med 277:1336-1340
224. Chapel HM, Lee M, Hargreaves R et al (1994) Randomized trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myeloma. Lancet 343:1059-1063